Richard Francis, Teva CEO (Dylan Martinez/Reuters)
July 31, 2024 03:23 PM EDT
Pharma

Te­va fac­tored IRA's next round of ne­go­ti­a­tions in­to its growth plans

Nicole DeFeudis

Editor

Te­va is con­fi­dent in the next phase of its “piv­ot to growth” strat­e­gy — even in the face of up­com­ing se­lec­tions for the next round of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times